Clinical Trial

Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a single arm, open label, multi-center phase I study, including phase Ia dose escalation and phase Ib dose expansion. Safety review committee (SRC) will be formed to monitor safety and efficacy data through the study. And the independent review committee (IRC) will be formed to monitor efficacy data through the study.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-02-19; most recent amendment 2026-06-08.
Status change: Not Yet Recruiting → Recruiting 2025-03-20
Trial Details
NCT Number NCT06278454
Lead Sponsor Chengdu New Radiomedicine Technology Co. LTD.
Conditions Unresectable Pancreatic Cancer, Advanced Pancreatic Cancer, Lymph Node Metastases
Enrollment 58 participants
Start Date 2024-01-09
Primary Completion 2027-12 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-10